




Journal American Chemical Society (2026) 148 (33): 35245–35249.



C)			MIC (µg/mL)	
			17 (rif M)	rif S
Strain ID				
<i>S. aureus</i>	ATCC 12600	WT	≤0.5	≤0.5
<i>S. aureus</i>	USA300	MRSA-rif ^S	≤0.5	≤0.5
<i>E. faecalis</i>	ATCC 19433	WT	4	1
<i>S. aureus</i>	CDC-AR-219	VISA-rif ^R	32	>64
<i>S. aureus</i>	CDC-AR-226	VISA-rif ^R	32	>64
<i>E. faecium</i>	CDC-AR-500	VVE-rif ^R	64	16

Figure 2. A) Synthetic reassembly: a) NaH, THF (60–70%); b) Grubbs II, PhMe, 80 °C, 6 h; Bu₄NF (**16a**) (12%); **16b** (23%); c) CAN, CH₃CN, H₂O, 30 min; d) MgI₂, Et₂O (62% over 2 steps). B) Kirby–Bauer disk diffusion assay with *S. aureus* ATCC 12600: DMSO control. Zone of inhibition = 24 mm for rifamycin 5 µg/disk, 26 mm rifalene M (17) 10 µg/disk, 25 mm (17) 5 µg/disk and 23 mm (17) 2.5 µg/disk. C) CLSI-MICs of 17 compared to rifamycin S.